Edwards Lifesciences Corp. reported an insider ownership change involving Annette Bruls, with the transaction dated July 11, 2026, and the Form 4 filed on July 13, 2026. The filing indicates that the transaction involved Edwards Lifesciences common stock and consisted of shares withheld by the company to satisfy tax withholding obligations connected with the vesting of securities. This type of transaction is typically reported on Form 4 with transaction code “F,” reflecting a disposition of shares back to the issuer for tax purposes rather than an open-market sale. The filing cites Rule 16b-3(e), which covers certain exempt transactions between an issuer and its officers or directors, including tax withholding related to equity compensation vesting. The document does not provide the number of shares withheld, the deemed transaction price, or Annette Bruls’ beneficial ownership after the transaction in the text provided. It also does not identify the specific vesting award, such as restricted stock units or another equity grant, beyond stating that the withholding occurred “incident to the vesting of securities.” A key explanatory note states that the Form 4 reflects only changes in beneficial ownership and does not identify all other Edwards Lifesciences securities beneficially owned by Bruls. The filing was signed on Bruls’ behalf by Linda J. Park, attorney-in-fact, on July 13, 2026. In practical terms, the filing reports an administrative equity-compensation event rather than a discretionary insider sale. Shares were withheld by Edwards Lifesciences to cover tax obligations triggered by vesting, which reduces the insider’s reported holdings but does not necessarily indicate a change in investment outlook by the reporting person.